Skip to content

Precigen

US · PGEN #2527 by market cap Listed 1970
4.21 +0.05 +1.20%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 19.40 Expensive vs history 80th percentile
5-year average 10.99 · #487 of 514 in Biotechnology
P/E ratio 41.27 Expensive vs history 100th percentile
5-year average -0.84 · forward 8.43 · #59 of 77 in Biotechnology
P/S ratio 10.37 Cheap vs history 28th percentile
5-year average 69.39 · forward 4.26 · #177 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Precigen (PGEN) 1.51B 38.27 17.99 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value4.37 Economic moatNone UncertaintyHigh

Trading 3.9% below Morningstar's fair value estimate.

Fair value

Precigen Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 3% premium over our quantitative fair value estimate of $4.37 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's valuation metrics weaken our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 5.2%, which lies in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.

The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's cash flow yield of 2.2%, for example, lies in the bottom 30% compared with peers globally. At the current valuation, the yield of cash flow from operations to investors looks paltry. This characteristic further promotes our unfavorable price/fair value ratio.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

Precigen discussion 0 comments

Add a comment